Browse News
Filter News
Found 14 articles
-
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
-
Faze Medicines Appoints New Senior Vice President, Head of People & Culture
8/5/2021
Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, announced that Daryn Lewis has joined the company as Senior Vice President, Head of People & Culture.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Faze Medicines Appoints Douglas Kerr, M.D., Ph.D., to its Board of Directors
5/4/2021
Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Douglas Kerr, M.D., Ph.D., to its board of directors.
-
BioSpace Movers & Shakers, Jan. 29
1/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
1/25/2021
Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO).
-
Biopharma Money on the Move: December 9-15
12/16/2020
A roundup of life sciences companies raking in the cash. -
Cambridge-based Faze Medicines, the biotechnology company that develops therapeutics based on biomolecular condensates, announced today that it has raised $81 million in a Series A round of financing.
-
Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease
12/10/2020
Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced its launch and Series A financing of $81 million.
-
The company is presenting the study during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday, May 31.
-
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
11/19/2019
Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol. -
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
-
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
-
BioPharm Executive: 5 Reasons To Hate Biotech
10/29/2014